The study of mismatch repair in endometrial cancer patients with a family history of cancer by Buchynska, L.G. et al.
272 Experimental Oncology 37, 272–276, 2015 (December)
THE STUDY OF MISMATCH REPAIR IN ENDOMETRIAL CANCER 
PATIENTS WITH A FAMILY HISTORY OF CANCER
L.G. Buchynska1, O.V. Brieieva1*, K.A. Nekrasov2, S.V. Nespryadko3
1R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, 
Kyiv 03022, Ukraine
2Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv 03680, Ukraine
3National Cancer Institute, MH of Ukraine, Kyiv 03022, Ukraine
Aim: To assess the expression of mismatch repair (MMR) proteins MSH2 and MLH1 and carry out microsatellite analysis in pa-
tients with endometrial cancer (EC) with regard to the family history of cancer. Materials and Methods: Morphological and im-
munohistochemical study was performed on tumor tissue samples of 49 EC patients. Microsatellite instability was determined 
using PCR with primers which flank microsatellite region BAT-26. Results: A tendency to a decreased expression of both MSH2 and 
MLH1 markers in a group of EC patients with a family history of cancer as compared with a group without aggregation of cancer 
in family history was observed (labeling index — LI — was 36.1 ± 8.1% and LI 20.7 ± 9.1% versus LI 48.0 ± 5.8% and 33.8 ± 
5.8%, respectively). It was determined that the number of EC patients with tumors deficient by expression of MMR markers was 
reliably higher in a group of patients with a family history of cancer than in a group of patients without aggregation of cancer 
in fami ly history (р < 0.05). It was shown that in a group of EC patients with a family history of cancer, MMR-proficient tumors 
were detected in 38.5% of cases. Microsatellite instability was determined in 10.7% of EC patients including one patient with ag-
gregation of Lynch-associated tumors in family history. Conclusion: Family history of cancer of EC patients is associated with 
malfunctioning of the MMR system as well as may be related to alternative molecular mechanisms.
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It is known today that approximately 5–10% of ma-
lignant neoplasms occur in the result of hereditary 
predisposition to cancer caused by the germinal muta-
tions in genes which are associated with increased risk 
of cancer [1, 2]. Endometrial cancer (EC) may occur 
due to the series of hereditary cancer syndromes, 
among which Lynch syndrome (hereditary non-polypo-
sis colorectal cancer) is the most prevalent. The specific 
feature of Lynch syndrome is a presence of germinal 
mutations in genes MSH2, MLH1, MSH6, and PMS2, 
which belong to the mismatch repair (MMR) system [3].
MMR provides improvement of non-complemen-
tary base pairs, which in high amount emerge in the 
process of DNA replication. Genetic or epige netic 
disorders of this system cause the development 
of microsatellite instability (MSI) that manifests itself 
by microdeletions and microinsertions in the regions 
of location of mono-, di-, tri- and tetranucleotide re-
peats of DNA. At accumulation of non-repaired micro-
deletions and microinsertions in microsatellites, which 
are located in coding and regulatory regions of proto-
oncogenes and suppressor genes, shift of the reading 
frame and change of expression of these genes occurs 
that can be the reason of malignant transformation [4]. 
According to some data, effectiveness of functioning 
of MMR significantly determines the aggressiveness 
of tumor process that can be used at the choice 
of EC treatment strategy [5].
In 1913, Lynch syndrome was first time described 
by Warthin on the example of family, in the history 
of which aggregation of endometrial tumors and gas-
trointestinal cancer was observed. Today Lynch-associ-
ated neoplasms include tumors of colon, endometrium, 
gastric, ovary, pancreas, bile ducts, and urogenital 
system as well as tumors of some other localization [3]. 
Lynch syndrome in patients with colorectal cancer 
is diagnosed basing on the Amsterdam criteria [6, 7] 
and Bethesda recommendations [8, 9]. The last ones, 
along with the assessment of family history of proband, 
require carrying out of molecular-genetic tests. Re-
cently specified recommendations concerning detec-
tion of individuals with Lynch syndrome among patients 
with EC were published [3, 10]. It should be noted that 
number of researchers have evaluated the dissemina-
tion of Lynch syndrome via determination of hereditary 
mutations and it was detected that its frequency was 
within the limits of 2.0–4.6% [11–15].
Some authors assume the existence of particular 
hereditary syndrome of EC, at which proband has 
a family history of this disease and no mutations in MMR 
genes [16]. The last argues the necessity of carrying out 
of further studies concerning the detection of peculiari-
ties of cancer pathology aggregation in family history 
of patients with EC and its molecular mechanisms.
This research aims to assess the expression 
of MMR proteins and analyze MSI in EC patients re-
garding the family history of cancer.
MATERIALS AND METHODS
Morphological, immunohistochemical tests and 
microsatellite analysis were carried out on samples 
of tumor tissue of 49 patients with EC of I and II stages 
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who underwent surgery in the Research Department 
of Cancer Gynecology of the National Cancer Institute 
of Ministry of Health of Ukraine. Mean age of patients 
was 59.0 ± 1.7 years. All patients have given written 
informed consent for participation in the study.
To analyze family history of probands, special ge-
nealogical questionnaire, which contained information 
on diseases of relatives, life conditions of the patient 
and concomitant diseases, was used. As criteria for 
attributing of the EC patients to the group of individu-
als with a family history of cancer was the presence 
of malignant tumors of female reproductive system 
and/or other Lynch-associated tumors in relatives 
of probands of I–II degree of the relationship [3].
Morphological study was carried out on the speci-
mens dyed with hematoxylin and eosin. Assessment 
of expression of key markers of the MMR-system 
was conducted using immunohistochemical method 
with monoclonal antibodies MSH2 (clone 25D12) and 
MLH1 (clone G168–15) (“Diagnostic BioSystems”, 
USA). To visualize mentioned proteins, detection 
PolyVue system (“Diagnostic BioSystems”, USA) was 
used. Results of immunohistochemical reaction were 
assessed by calculation of the number of stained 
cells, which was determined in percentage (labeling 
index — LI, %). Expression of markers was assessed 
in 800–1000 tumor cells.
Microsatellite analysis was carried out using PCR 
with primers that flank microsatellite region BAT-26 [17]. 
Genomic DNA was isolated from tumor tissues and 
peripheral blood lymphocytes via phenol-chloroform 
extraction. Nucleotide sequence of primers was the 
following: Forward: 5-TGACTACTTTTGACTTCAGCC-3 
and Reverse: 5- ACCATTCAACATTTTTAACCC-3. PCR 
was carried out in 20 μL of PCR buffer that contained 
2.5 mM MgCl2, 200 mM of each dNTP, 0.3 mM of each 
primer, 100 ng of DNA and 2 U Taq-polymerase. 
The mixture was warmed up to 95 °C for 5 min and 33 cy-
cles of amplification were carried out with parameters: 
denaturation 94 °C — 30 s, annealing 58 °C — 30 s and 
elongation 72 °C — 30 s.
Products of PCR were separated by electrophoresis 
in 15% polyacrylamide gel at 120 V during 12 h and 
were stained with SYBR Green. MSI was confirmed 
at emergence of alleles, length of which differed from 
the normal ones, which were detected in DNA from 
peripheral blood lymphocytes.
Statistical processing of data was carried using 
program package Statistica 8.0 (StatSoft, Inc.) with the 
help of Mann — Whitney nonparametric criterion and 
Fisher criterion. Reliable were considered differences 
at р < 0.05.
RESULTS AND DISCUSSION
Verification of morphological diagnosis has deter-
mined that all studied endometrial tumors were endome-
trioid adenocarcinomas of various differentiation grades: 
6 — well, 25 — moderately and 18 — poorly differentiated 
tumors. Immunohistochemical study has detected that 
positive expression of MSH2 protein was found in 75.5% 
(37 out of 49 cases), and MLH1 protein — 57.1% (28 out 
of 49 cases) of endometrial tumors and mean number 
of cells, which express these proteins, was 44.6 ± 4.8% 
and 30.1 ± 5.0%, respectively (Fig. 1).
a
b
Fig. 1. Expression of MMR proteins MSH2 and MLH1 in modera-
tely differentiated endometrial adenocarcinoma (a); poorly diffe-
rentiated endometrial adenocarcinoma (b). Immunohistochemical 
method, stained with Mayer’s hematoxylin, × 400
Clinical and genealogical analysis of family histories 
of EC patients has showed that 13 (26.5%) out of 49 pro-
bands had a family history of cancer. It was determined 
that mostly tumors of female reproductive system and 
gastrointestinal tract were accumulated in families 
(Table 1, Fig. 2) that fits our results obtained in previous 
studies [18]. Tumors were observed in 5 (71.4%) mo-
thers and 2 siblings (28.6%) among first degree relatives 
of EC patients and in 6 aunts (54.7%), 3 grandmothers 
(27.3%), 1 uncle (9.0%) and 1 niece (9.0%) among 
second degree relatives.
Table 1. Malignant tumors in relatives of EC patients
Degree of relationship
Localization of tumors and their quantity 
in proband families
Endome-
trium Breast
Gastro-
intestinal 
tract
Ovary Total
І (mother, father, sister, bro-
ther, children)
1 2 3 1 7
ІІ (aunt, uncle, grandmother, 
grandfather, nephew, niece)
5 4 2 0 11
Total 6 6 5 1 18
Comparison of expression of MSH2 marker in pa-
tients with EC from the families with a family history 
of cancer has not determined reliable difference in the 
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number of MSH2-positive cases as compared to the 
group of patients without aggregation of cancer pa-
thology in family history. However, for MLH1 protein, 
significant difference was determined between these 
indexes in groups of EC patients with aggregation and 
without aggregation of cancer in family (p < 0.05) (Ta-
ble 2). Also, it was determined that in a group of EC pa-
tients with a family history of cancer, a tendency to de-
creased expression of MSH2 marker as compared with 
a group without aggregation of cancer in family was 
observed (LI 36.1 ± 8.1 and 48.0 ± 5.8%, respectively). 
The expression of MLH1 changed in the same way 
(LI 20.7 ± 9.1 and 33.8 ± 5.8%, respectively).
I
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55
Fig. 2. Pedigree of proband with EC. In relatives of I and II degree 
of relationship, aggregation of Lynch-associated tumors is ob-
served: EC, gastric cancer (GC) and colorectal cancer (CRC)
Taking into account the fact that a lack of at least 
one of the MMR-proteins causes the malfuncti oning 
of the whole MMR system, we have determined two 
groups of tumors by expression of MSH2 and MLH1: 
MMR-deficient (lack of both or one of MMR-proteins) 
and MMR-proficient (presence of both MMR-pro-
teins) [19, 20]. It was determined that the number 
of EC patients with MMR-deficient tumors was reli-
ably higher in a group of patients with a family history 
of cancer (8 out of 13) while in a group of patients 
without family history of cancer their number was 
27.8% (10 out of 36) (p < 0.05) (Table 3).
Table 3. Comparing number of MMR-deficient and MMR-proficient tumors 
in EC patients depending on familial aggregation of cancer
Groups of examined patients
Number 
of MMR-defi-
cient tumors, 
n (%)
Number 
of MMR-profi-
cient tumors, 
n (%)
Patients with a family history of cancer 8 (61.5) 5 (38.5)
Patients with no family history of cancer 10 (27.8) 26 (72.2)
p p < 0.05 (F test)
Data stated above show that tumors of EC patients 
with a family history of cancer are characterized by the 
defects in expression of key proteins of the MMR sys-
tem MSH2 and MLH1 to a greater extent than tumors 
of patients, which emerged sporadically. The further 
analysis of a group of patients with a family history 
of cancer has showed that out of 8 EC patients with 
MMR-deficient tumors, aggregation of cancer pa-
thology by the type of Lynch syndrome was observed 
in 5 (10.2%) of them that allows to pre-include these 
patients in the group of patients with suspected Lynch 
syndrome. According to the data of literature, for the 
final diagnosis of the Lynch syndrome, molecular-
genetic test with detection of hereditary mutations 
in MMR genes in patient and her relatives has to be car-
ried out. Such test is recommended to perform after 
previous immunohistochemical detection of the 
4 MMR-proteins (MSH2, MLH1, MSH6 and PMS2) 
and assessment of promoter methylation status 
of MLH1 gene in the case of lack of its expression [3].
In three examined EC patients with a family history 
of cancer and MMR-deficient tumors in family histo-
ries, along with tumors of gastrointestinal tract, breast 
tumors were observed that according to the ideas 
of the number of researchers indicates the possibility 
of referring of breast tumors to the Lynch-associated 
tumors [21, 22], but this issue remains disputable.
In group of 5 EC patients with MMR-proficient tu-
mors and a family history of cancer (38.5%), 2 patients 
had familial aggregation of EC, 2 other patients — breast 
cancer, and in 1 case — aggregation of gastrointesti-
nal cancers by the type of Lynch syndrome. Presence 
of EC in family histories of patients of this group fits the 
data of other researchers on the existence of particular 
hereditary syndrome of EC, which is not associated 
with malfunctioning of MMR-system [11, 23]. Presence 
of breast cancer in family histories of EC patients also 
may be not random and allows to assume possibi lity 
of existence of hereditary syndrome “breast can-
cer — endometrial cancer” that was reported by Wendt 
et al. [24]. At the same time, mutations at Lynch syn-
drome occur not only in MSH2 and MLH1 genes, but 
also in MSH6 and PMS2 genes. For this reason, one 
cannot exclude that in patients with MMR-proficient EC, 
hereditary aggregation is caused by germinal mutations 
in genes MSH6 and PMS2, expression of which was not 
analyzed in this study.
Taking into account that genetic and epigenetic 
changes of MMR genes cause MSI, we have carried 
out microsatellite analysis by marker BAT-26 in en-
dometrial adenocarcinomas of 28 patients. MSI was 
detected in 3 cases (10.7%) (Fig. 3). This rate turned 
out to be lower as compared with frequency of MSI, 
which was determined by other researchers that pro-
bably is associated with different prevalence of MSI 
in different ethnic groups [28]. For instance, accord-
ing to the literature, MSI is detected in 25–30% of all 
endometrial carcinomas [25]. It should be noted that 
studies of Ichikawa et al. [26], and Risinger et al. [27] 
have showed that 75% of Lynch-associated endo-
metrial adenocarcinomas are characterized by pre-
Table 2. Assessment of expression of MMR markers in tumors of EC patients depending on familial aggregation of cancer
Groups of examined patients
Number of tumors with expression of markers, % LI, %
Mean ± SEMSH2 MLH1
Positive expression, 
n (%) 
Lack expression, 
n (%)
Positive expression, 
n (%)
Lack expression, 
n (%) MSH2 MLH1
Patients with a family history of cancer 9 (70.2) 4 (30.8) 4 (55.5) 7 (54.5) 36.1 ± 8.1 20.7 ± 9.1
Patients without family history of cancer 29 (82.8) 6 (17.2) 29 (80.5) 7 (19.5) 48.0 ± 5.8 33.8 ± 5.8
p p > 0.05 (F test) p < 0.05 (F test) p > 0.05 (Mann — Whitney test)
p > 0.05 (Mann — 
Whitney test)
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sence of MSI. Among EC patients, in whom MSI was 
determined, Lynch-associated tumors were observed 
in family history of one patient. Our data on frequency 
of MSI among EC patients with a family history of can-
cer may be confirmation of existence of alternative 
molecular mechanisms, which cause the development 
of hereditary forms of cancer.
L T L T L Ta b c
Fig. 3. Results of microsatellite analysis using BAT-26 marker. 
MSI is confirmed in 3 cases (a, b, c) that is evidenced by the 
emergence of alleles of other length in tumor DNA (marked 
by arrow) as compared with DNA from peripheral blood lym-
phocytes. L — PCR product from lymphocyte DNA, T — PCR 
product from tumor DNA
Thus, the results of our study show that family history 
of cancer in EC patients is associated with malfunction 
of the system of MMR. At the same time, obtained 
data allow to assume the existence of other molecular 
mechanisms, which stipulate the development of he-
reditary forms of cancer. It also has to be taken into 
account that a family history of cancer may be caused 
not only by genetic factors, but also by environmental 
exogenous factors, which influence the members of the 
same family. For instance, the results of studies of Seger 
et al. [29] show that risk of EC was higher in relatives 
with EC with high body mass index as compared with 
patients, whose indexes were low or average.
It should be noted that prognostic impact of MMR 
deficiency on outcome of EC remains unclear. Some stu-
dies didn’t find any association between MMR deficiency 
and outcome in EC patients [30, 31]. By contrast, Nout 
et al. [32] reported association with decreased survival. 
In addition, de Jong et al. [33] showed that patients with 
the loss of MMR protein expression had a worse disease 
specific survival compared to patients with its expression. 
Further studies are needed to clarify impact of MMR 
status on outcome of the disease in EC patients with 
family history of cancer.
Understanding of mechanisms of development 
of familial cancers is a basis for the search of new bio-
markers, by which hereditary predisposition to cancer 
may be determined. Such approach contributes to the 
effective formation of groups with high risk of cancer 
and primary prophylaxis of cancer diseases. Detection 
of individuals with suspected Lynch syndrome or other 
hereditary syndromes among EC patients will allow phy-
sicians to provide these patients and their relatives with 
required recommendations concerning the lifestyle and 
use adequate procedures to prevent cancer diseases.
CONCLUSIONS
Family history of cancer in EC patients is accom-
panied with the malfunctioning of the MMR-system 
that is associated with decreased expression of MMR-
proteins and increase of number of MMR-deficient tu-
mors among EC patients with family history of cancer. 
MSI was determined in 10.7% of EC patients. MMR-
proficient tumors were found in 38.5% of EC patients 
with aggregation of cancer in family history that may 
indicate existence of alternative molecular mecha-
nisms, which cause the development of hereditary 
forms of cancer.
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